I agree that this site is using cookies. You can find further informations here.
X
Sethuraman, Gopalan
86  results:
Search for persons X
?
1

Recruitment strategies and tactics for INTERCEPT‐AD: A phas..:

Moxon, Robyn ; Feaster, Todd ; Carroll, Alyssa...
Alzheimer's & Dementia.  19 (2023)  S24 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
2

Baseline characteristics of INTERCEPT‐AD: A phase 1 trial w..:

Feaster, Todd ; Ziemba, Shane ; Sundell, Karen L...
Alzheimer's & Dementia.  19 (2023)  S24 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
3

Natural cubic splines for the analysis of Alzheimer's clini..:

Donohue, Michael C. ; Langford, Oliver ; Insel, Philip S....
Pharmaceutical Statistics.  22 (2023)  3 - p. 508-519 , 2023
Link: https://doi.org/10.1002/..
 
?
4

Topline results of INTERCEPT‐AD: A phase I trial of Aβ olig..:

Siemers, Eric R ; Feaster, Todd ; Skljarevski, Vladimir...
Alzheimer's & Dementia.  19 (2023)  S24 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
5

The Institute on Methods and Protocols for Advancement of C..:

Grill, Joshua ; Berkness, Tyler ; Carrillo, Maria C....
Alzheimer's & Dementia.  18 (2022)  S10 - p. , 2022
Link: https://doi.org/10.1002/..
 
?
6

The AHEAD 3‐45 Study: Design of a prevention trial for Alzh..:

Rafii, Michael S. ; Sperling, Reisa A. ; Donohue, Michael C....
Alzheimer's & Dementia.  19 (2022)  4 - p. 1227-1233 , 2022
Link: https://doi.org/10.1002/..
 
?
7

AHEAD 3‐45 study: Preliminary screening and baseline charac..:

Zhou, Jin ; Irizarry, Michael C ; Kramer, Lynn D...
Alzheimer's & Dementia.  17 (2021)  S9 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
8

AHEAD 3‐45 study design: A global study to evaluate the eff..:

Aisen, Paul S. ; Zhou, Jin ; Irizarry, Michael C....
Alzheimer's & Dementia.  16 (2020)  S9 - p. , 2020
Link: https://doi.org/10.1002/..
 
?
9

Alternatives to MMRM for preclinical Alzheimer's clinical t..:

Donohue, Michael C. ; Sethuraman, Gopalan ; Langford, Oliver...
Alzheimer's & Dementia.  16 (2020)  S9 - p. , 2020
Link: https://doi.org/10.1002/..
 
?
10

Representativeness of European clinical trial populations i..:

Reed, Catherine ; Belger, Mark ; Dell'Agnello, Grazia...
Alzheimer's Research & Therapy.  10 (2018)  1 - p. , 2018
Link: https://doi.org/10.1186/..
 
?
11

A novel cognitive disease progression model for clinical tr..:

Wang, Guoqiao ; Berry, Scott ; Xiong, Chengjie...
Statistics in Medicine.  37 (2018)  21 - p. 3047-3055 , 2018
Link: https://doi.org/10.1002/..
 
?
12

[P1–044]: SAFETY OF SOLANEZUMAB IN PHASE 3 STUDIES IN INDIV..:

Carlson, Christopher D. ; Anglin, Greg ; Case, Michael G....
Alzheimer's & Dementia.  13 (2017)  7S_Part_5 - p. , 2017
Link: https://doi.org/10.1016/..
 
?
13

P2‐007: Exposure‐Adjusted Analysis of Treatment‐Emergent Ad..:

Carlson, Christopher D. ; Hake, Ann Marie ; Sethuraman, Gopalan...
Alzheimer's & Dementia.  12 (2016)  7S_Part_12 - p. , 2016
Link: https://doi.org/10.1016/..
 
?
14

Phase 3 solanezumab trials: Secondary outcomes in mild Alzh..:

Siemers, Eric R. ; Sundell, Karen L. ; Carlson, Christopher...
Alzheimer's & Dementia.  12 (2015)  2 - p. 110-120 , 2015
Link: https://doi.org/10.1016/..
 
?
15

Delayed‐start analysis: Mild Alzheimer's disease patients i..:

Liu‐Seifert, Hong ; Siemers, Eric ; Holdridge, Karen C....
Alzheimer's & Dementia: Translational Research & Clinical Interventions.  1 (2015)  2 - p. 111-121 , 2015
Link: https://doi.org/10.1016/..
 
1-15